WASHINGTON — Implantation of the Xen gel stent can effectively control IOP in patients with glaucoma in the long term, but the stent also demonstrates potentially high rates of reoperation and bleb-related infections, a speaker said here.
At the American Glaucoma Society annual meeting, Hari Jayaram, MA (Hons), MSc, MBMCh, PhD, FRCSEd, shared the 4-year results of a retrospective case note review of all Xen transscleral gel stent (Allergan) procedures performed between 2012 and 2018 at Moorfields Eye Hospital in the United Kingdom.
“When the stent is successful and further revision
Uncategorized